BRPI0721259C1 - composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto - Google Patents
composto, composição farmacêutica, uso de composto, e, processo para a fabricação de compostoInfo
- Publication number
- BRPI0721259C1 BRPI0721259C1 BRPI0721259A BRPI0721259A BRPI0721259C1 BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1 BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1
- Authority
- BR
- Brazil
- Prior art keywords
- compost
- tyr
- pharmaceutical composition
- making
- dpro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Non-Reversible Transmitting Devices (AREA)
Abstract
composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto. os peptidomiméticos tipo grampo de cabelo (beta) fixados sobre matriz ciclo(-tyr-his-x-cys-ser-ala-dpro-dab-arg-tyr-cys-tyr-gln-lys- pro-pro), ligação de dissulfeto entre cys4 e gys11, e sais farmaceuticamente aceitáveis destes, com x sendo ala ou tyr, têm propriedades antagonizadoras cxcr4 e podem ser usados para prevenir infecções por hiv em indivíduos saudáveis ou para diminuir e parar a progressão viral em pacientes infectados; ou onde o câncer é mediado ou resultante da atividade receptora de cxcr4; ou onde as doenças imunológicas são mediadas ou resultantes da atividade receptora de cxcr4; ou para tratar a imunossupressão; ou, em particular, para a mobilização das células tronco das células tronco do sistema periférico e/ou célula tronco mesenquimal (msc) e/ou outras células tronco cuja retenção depende do receptor de cxcr4. estes peptidomiméticos tipo grampo de cabelo (beta) podem ser fabricados através de um processo que é fundamentado em um estratégia sintética de fase sólida e de solução, usando métodos que são bem, conhecidos àqueles adequadamente habilitados na química peptídica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CH2007/000101 WO2008104090A1 (en) | 2007-02-28 | 2007-02-28 | Template-fixed peptidomimetics |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0721259A2 BRPI0721259A2 (pt) | 2013-01-15 |
BRPI0721259B1 BRPI0721259B1 (pt) | 2020-04-07 |
BRPI0721259B8 BRPI0721259B8 (pt) | 2020-09-15 |
BRPI0721259C1 true BRPI0721259C1 (pt) | 2021-05-25 |
Family
ID=37891752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0721259A BRPI0721259C1 (pt) | 2007-02-28 | 2007-02-28 | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto |
Country Status (21)
Country | Link |
---|---|
US (7) | US8399611B2 (pt) |
EP (1) | EP2132221B1 (pt) |
JP (1) | JP5140686B2 (pt) |
KR (1) | KR101479148B1 (pt) |
CN (1) | CN101641372B (pt) |
AT (1) | ATE475667T1 (pt) |
AU (1) | AU2007348171B2 (pt) |
BR (1) | BRPI0721259C1 (pt) |
CA (1) | CA2679414C (pt) |
DE (1) | DE602007008150D1 (pt) |
DK (1) | DK2132221T3 (pt) |
EA (1) | EA017583B1 (pt) |
ES (1) | ES2349879T3 (pt) |
HK (1) | HK1138011A1 (pt) |
IL (1) | IL200312A (pt) |
MX (1) | MX2009008843A (pt) |
NO (1) | NO342598B1 (pt) |
NZ (1) | NZ579875A (pt) |
PL (1) | PL2132221T3 (pt) |
PT (1) | PT2132221E (pt) |
WO (1) | WO2008104090A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007079597A1 (en) | 2006-01-16 | 2007-07-19 | Polyphor Ltd. | Template - fixed peptidomimetics with antimicrobial activity |
CA2676865C (en) | 2007-01-29 | 2018-09-25 | Polyphor Ltd. | Template - fixed peptidomimetics |
AU2007348171B2 (en) | 2007-02-28 | 2012-09-06 | Polyphor Ltd. | Template-fixed peptidomimetics |
EP2427476B1 (en) * | 2009-05-07 | 2018-08-08 | Polyphor Ag | Beta-hairpin peptidomimetics having cxcr4 antagonizing activity |
WO2011066869A1 (en) * | 2009-12-04 | 2011-06-09 | Polyphor Ag | Beta-hairpin peptidomimetics |
BR112013029482A2 (pt) | 2011-05-16 | 2016-08-09 | Genzyme Corp | utilização de antagonistas cxr4 |
BR112013031575B1 (pt) * | 2011-06-07 | 2021-03-16 | Polyphor Ag | Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto |
ES2576959T3 (es) * | 2011-10-07 | 2016-07-12 | Polyphor Ag | Peptidomiméticos fijados sobre plantilla como inhibidores del FPR1 |
JP6047231B2 (ja) * | 2012-06-06 | 2016-12-21 | ポリフォー・アクチェンゲゼルシャフトPolyphor Ag | β−ヘアピンペプチド模倣薬 |
EP2882770B1 (en) * | 2012-08-08 | 2017-05-31 | Polyphor AG | Combinations with a backbone-cyclized peptide |
WO2020071520A1 (ja) * | 2018-10-05 | 2020-04-09 | 株式会社ステムリム | 間葉系幹細胞の動員活性を有するペプチド |
WO2022106061A1 (en) | 2020-11-19 | 2022-05-27 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
WO2022184320A2 (en) | 2021-03-03 | 2022-09-09 | Spexis Ag | Medical use of cyclic peptides |
WO2023285681A1 (en) | 2021-07-16 | 2023-01-19 | Spexis Ag | Pharmaceutical combinations for treating cancer |
WO2023285677A1 (en) | 2021-07-16 | 2023-01-19 | Spexis Ag | Pharmaceutical combinations for treating cancer |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2382931C (en) * | 1999-08-30 | 2011-01-25 | Polyphor Ag | Synthesis of template-fixed .beta.-hairpin loop mimetics |
ES2527339T3 (es) * | 2001-02-23 | 2015-01-23 | Polyphor Ltd. | Peptidomiméticos fijados a patrón con actividad antimicrobiana |
CN101157924A (zh) | 2001-12-11 | 2008-04-09 | 人体基因组科学有限公司 | 嗜中性白细胞因子α |
WO2003057173A2 (en) * | 2002-01-07 | 2003-07-17 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
CN1688600B (zh) | 2002-08-20 | 2010-04-28 | 波利弗尔有限公司 | 具有抗菌活性的模板固定的肽模拟物 |
US7855179B2 (en) | 2002-10-02 | 2010-12-21 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
ATE395355T1 (de) | 2003-05-02 | 2008-05-15 | Polyphor Ag | Matrizenfixierte peptidmimetika als medikamente gegen hiv und krebs |
AU2003232253A1 (en) * | 2003-05-02 | 2004-11-23 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
US7681235B2 (en) | 2003-05-19 | 2010-03-16 | Radware Ltd. | Dynamic network protection |
ES2491166T3 (es) | 2003-11-15 | 2014-09-05 | Polyphor Ltd. | Miméticos de lazo de horquilla beta fijados a patrón y su utilización en exposición en fagos |
DK1856140T3 (en) | 2005-02-17 | 2014-03-10 | Polyphor Ltd | Matrix-fixed beta-hairpin shaped peptidomimetics with protease inhibitory activity |
WO2006117011A1 (en) | 2005-05-02 | 2006-11-09 | Polyphor Ltd. | Dye conjugates of template-fixed peptidomimetics |
WO2007079597A1 (en) | 2006-01-16 | 2007-07-19 | Polyphor Ltd. | Template - fixed peptidomimetics with antimicrobial activity |
CA2676865C (en) | 2007-01-29 | 2018-09-25 | Polyphor Ltd. | Template - fixed peptidomimetics |
AU2007348171B2 (en) | 2007-02-28 | 2012-09-06 | Polyphor Ltd. | Template-fixed peptidomimetics |
WO2010015287A2 (en) | 2008-08-08 | 2010-02-11 | Polyphor Ag | Template-fixed peptidomimetics |
WO2010060479A1 (en) | 2008-11-26 | 2010-06-03 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
EP2427476B1 (en) | 2009-05-07 | 2018-08-08 | Polyphor Ag | Beta-hairpin peptidomimetics having cxcr4 antagonizing activity |
US9695191B2 (en) | 2009-08-05 | 2017-07-04 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
WO2011060832A1 (en) | 2009-11-20 | 2011-05-26 | Polyphor Ag | Template-fixed peptidomimetics with ccr10 antagonistic activity |
WO2011066869A1 (en) | 2009-12-04 | 2011-06-09 | Polyphor Ag | Beta-hairpin peptidomimetics |
ES2570458T3 (es) | 2010-02-05 | 2016-05-18 | Polyphor Ag | Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7 |
WO2011095218A1 (en) | 2010-02-05 | 2011-08-11 | Polyphor Ag | Template-fixed pep tidomime tics with cxcr7 modulating activity |
US8895499B2 (en) | 2010-08-05 | 2014-11-25 | Polyphor Ag | β-hairpin peptidomimetics |
BR112013031575B1 (pt) | 2011-06-07 | 2021-03-16 | Polyphor Ag | Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto |
ES2576959T3 (es) | 2011-10-07 | 2016-07-12 | Polyphor Ag | Peptidomiméticos fijados sobre plantilla como inhibidores del FPR1 |
SG11201405628YA (en) | 2012-03-17 | 2014-10-30 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
JP6047231B2 (ja) | 2012-06-06 | 2016-12-21 | ポリフォー・アクチェンゲゼルシャフトPolyphor Ag | β−ヘアピンペプチド模倣薬 |
EP2882770B1 (en) | 2012-08-08 | 2017-05-31 | Polyphor AG | Combinations with a backbone-cyclized peptide |
RS56350B1 (sr) | 2012-08-08 | 2017-12-29 | Polyphor Ag | Kombinacije sa peptidom sa ciklizovanim osnovnim lancem |
US9938322B2 (en) | 2013-03-30 | 2018-04-10 | Polyphor Ag | β-hairpin peptidomimetics |
AU2014247189C1 (en) | 2013-03-30 | 2019-05-16 | Polyphor Ag | Beta-hairpin peptidomimetics |
WO2015096873A1 (en) | 2013-12-27 | 2015-07-02 | Polyphor Ag | Beta-hairpin peptidomimetics as selective elastase inhibitors |
BR112016015018B1 (pt) | 2013-12-27 | 2022-10-04 | Polyphor Ag | Composto peptídico ciclizado na cadeia principal, composição farmacêutica, uso de um composto, método para tratar uma infecção ou uma doença ou distúrbio, e, processo para a fabricação de um composto |
-
2007
- 2007-02-28 AU AU2007348171A patent/AU2007348171B2/en active Active
- 2007-02-28 US US12/528,926 patent/US8399611B2/en active Active
- 2007-02-28 WO PCT/CH2007/000101 patent/WO2008104090A1/en active Application Filing
- 2007-02-28 EA EA200901178A patent/EA017583B1/ru unknown
- 2007-02-28 BR BRPI0721259A patent/BRPI0721259C1/pt active IP Right Grant
- 2007-02-28 PL PL07701901T patent/PL2132221T3/pl unknown
- 2007-02-28 ES ES07701901T patent/ES2349879T3/es active Active
- 2007-02-28 DK DK07701901.6T patent/DK2132221T3/da active
- 2007-02-28 EP EP07701901A patent/EP2132221B1/en active Active
- 2007-02-28 PT PT07701901T patent/PT2132221E/pt unknown
- 2007-02-28 MX MX2009008843A patent/MX2009008843A/es active IP Right Grant
- 2007-02-28 CA CA2679414A patent/CA2679414C/en active Active
- 2007-02-28 DE DE602007008150T patent/DE602007008150D1/de active Active
- 2007-02-28 KR KR1020097020096A patent/KR101479148B1/ko active IP Right Grant
- 2007-02-28 CN CN2007800518841A patent/CN101641372B/zh active Active
- 2007-02-28 AT AT07701901T patent/ATE475667T1/de active
- 2007-02-28 NZ NZ579875A patent/NZ579875A/en unknown
- 2007-02-28 JP JP2009551913A patent/JP5140686B2/ja active Active
-
2009
- 2009-08-10 IL IL200312A patent/IL200312A/en active IP Right Grant
- 2009-09-28 NO NO20093064A patent/NO342598B1/no unknown
-
2010
- 2010-03-25 HK HK10103116.1A patent/HK1138011A1/en unknown
-
2013
- 2013-02-11 US US13/764,099 patent/US8921325B2/en active Active
-
2014
- 2014-11-28 US US14/555,796 patent/US9556234B2/en active Active
-
2016
- 2016-12-15 US US15/379,820 patent/US9879047B2/en active Active
-
2017
- 2017-12-21 US US15/851,270 patent/US10144765B2/en active Active
-
2018
- 2018-11-14 US US16/190,459 patent/US10787486B2/en active Active
-
2020
- 2020-09-04 US US17/013,111 patent/US11421001B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0721259B8 (pt) | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto | |
BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
CL2003002731A1 (es) | Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe | |
WO2007022257A3 (en) | Monocyclic and bicyclic compounds and methods of use | |
BR122016022033B8 (pt) | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica | |
CL2011002056A1 (es) | Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras. | |
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
MX2009003129A (es) | Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras. | |
EP3744340A3 (en) | Compositions and methods for treating cancer | |
WO2010068287A8 (en) | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
BRPI0918517B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
WO2008103378A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
MY146671A (en) | Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents | |
MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
WO2008049098A3 (en) | ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 | |
TW200716555A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
CL2008001322A1 (es) | Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2570 DE 07/04/2020 QUANTO AO INVENTOR. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B22B | Petition not considered [chapter 22.2 patent gazette] |
Free format text: NAO CONHECIDA A PETICAO NO 870210067284, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI |